Hepatitis B News and Research

Latest Hepatitis B News and Research

Automated diagnostic technologies redefine infectious diseases

The diagnostics market for infectious diseases such as tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis C virus and human papilloma virus is expanding, giving rise to commercial opportunities especially in the developing economies of Asia, Africa and Latin America.

22 Apr 2014

Doctors must consider factors when administering combination vaccines, say researchers

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive option, according to a new study by University of Illinois researchers.

22 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

UnitedHealth cites health law, costly hepatitis drug in reporting lower earnings

The health law's effect was mixed, officials said, because the company did not participate in many of the online marketplaces, but it did see more customers for its Medicaid plans. Officials are considering a bigger role in the marketplaces next year.

21 Apr 2014

Skin docs prescribe costlier drugs after free samples

In other news, panels recommend a costly hepatitis C drug for the sickest patients, and cancer doctors will compare the value of costly cancer drugs.

18 Apr 2014

Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study.

18 Apr 2014

First Edition: April 17, 2014

Today's headlines include reports about emerging political strategies related to the health law and the upcoming congressional elections.

17 Apr 2014

UnitedHealth Group reports strong revenue growth in Q1 2014

UnitedHealth Group today reported first quarter results, highlighted by Optum's strong growth in revenues, operating earnings and revenue backlog and UnitedHealthcare's continued strong, diversified performance despite the negative impacts of newly effective ACA taxes and regulatory provisions and sequestration cuts to Medicare.

17 Apr 2014

Entries now open for 2014 Quality in Care Hepatitis C programme

The first Quality in Care (QiC) Hepatitis C programme is now open for entry to teams and individuals working within the field of hepatitis C.

17 Apr 2014

Neurovive presents new breakthrough on energy regulation at cellular level

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level.

17 Apr 2014

Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Polls have consistently shown that even though the public opposes Obamacare, people like some of its most significant provisions. That's particularly true of the requirement that insurers ignore preexisting conditions when signing up customers for coverage.

16 Apr 2014

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Researchers at the University of California, San Diego School of Medicine have identified a mechanism that explains why people with the hepatitis C virus get liver disease and why the virus is able to persist in the body for so long.

16 Apr 2014

Community efforts boost people for HIV testing and reduce new infections

Communities in Africa and Thailand that worked together on HIV-prevention efforts saw not only a rise in HIV screening but a drop in new infections, according to a new study in the peer-reviewed journal The Lancet Global Health.

16 Apr 2014

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB).

16 Apr 2014

U.S. health care spending, usage rise

Americans' spending on medicines in 2013 rose 3.2 percent to nearly $330 billion, fueling speculation that a dip in overall health care spending may be over.

16 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

First Edition: April 15, 2014

Today's headlines include reports about the Congressional Budget Office's latest estimate of the costs for expanding health insurance.

15 Apr 2014

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).

15 Apr 2014

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.

15 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014

Hepatitis B News and Research

Latest Hepatitis B News and Research

Automated diagnostic technologies redefine infectious diseases

Doctors must consider factors when administering combination vaccines, say researchers

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

UnitedHealth cites health law, costly hepatitis drug in reporting lower earnings

Skin docs prescribe costlier drugs after free samples

Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

First Edition: April 17, 2014

UnitedHealth Group reports strong revenue growth in Q1 2014

Entries now open for 2014 Quality in Care Hepatitis C programme

Neurovive presents new breakthrough on energy regulation at cellular level

Viewpoints: Obamacare dilemma -- some people dislike the law but embrace its provisions; are health costs falling?

Researchers identify mechanism that explains reason for persistence of hepatitis C virus

Community efforts boost people for HIV testing and reduce new infections

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

U.S. health care spending, usage rise

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

First Edition: April 15, 2014

New data focuses on different approaches to improve diagnosis and treatment of HCC

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

New drug combination proves effective in treating patients with HCV genotype 1

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Hepatitis B News and Research

Latest Hepatitis B News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in